Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TEMPEST THERAPEUTICS, INC.

(TPST)
  Rapport
Vertraagde tijd Nasdaq  -  15:30 05-12-2022
1.750 USD   +3.55%
08/11Tempest Therapeutics, Inc. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
23/09Tempest Therapeutics, Inc. Kondigt wijzigingen in de leiding aan
CI
15/09Tempest Therapeutics, Inc. : Ladenburg Thalmann herhaalt koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op TEMPEST THERAPEUTICS, INC.
22/11Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
10/11Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with..
10/11Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with..
08/11TEMPEST THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
08/11Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
08/11Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
08/11Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
03/11Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-11..
02/11Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-11..
02/11Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-11..
06/10Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
06/10Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
23/09Tempest Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
23/09Tempest Therapeutics, Inc. Announces Executive Changes
08/09Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07/09Tempest to Present at the H.C. Wainwright 24th Annual†Global Investment Conference
07/09Tempest to Present at the H.C. Wainwright 24th Annual†Global Investment Conference
15/08TEMPEST THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
15/08Tempest Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Business..
15/08Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
15/08Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
15/08Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
07/07Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conferen..
07/07Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conferen..
21/06Tempest Therapeutics, Inc. : Change in Directors or Principal Officers, Submission of Matt..
09/06Tempest Therapeutics : Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Update..
09/06Tempest Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
09/06Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial ..
09/06Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial ..
09/06Tempest Therapeutics, Inc. Provides ASCO KOL Feedback on TPST-1120 Clinical Results
06/06Tempest to Present at the Jefferies Healthcare Conference
06/06Tempest Therapeutics : Investor Breakfast at 2022 ASCO Annual Meeting Presentation
26/05Tempest Therapeutics : Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Pati..
26/05Tempest Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
26/05Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Ad..
26/05Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Ad..
26/05Tempest Therapeutics Inc. Reports Positive TPST-1120 Clinical Data from Phase 1 Trial i..
16/05Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
13/05TEMPEST THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
13/05Tempest Reports First Quarter 2022 Financial Results and†Provides Corporate Highlights
13/05Tempest Reports First Quarter 2022 Financial Results and†Provides Corporate Highlights
13/05Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
04/05Insider Buy: Tempest Therapeutics
02/05Tempest Therapeutics : Announces Private Placement Financing of $15 Million - Form 8-K
02/05Tempest Therapeutics, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale..
29/04Tempest Therapeutics, Inc. announced that it has received $14.996793 million in funding..
27/04Top Midday Gainers
27/04Tempest Therapeutics to Raise $15 Million via Private Financing -- Shares Rise
27/04Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meetin..
27/04Tempest Announces Private Placement Financing of $15 Million
26/04Tempest Therapeutics, Inc. announced that it expects to receive $14.996793 million in f..
08/04Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR A..
29/03Tempest Therapeutics : Reports Year End 2021 Financial Results and Provides Corporate High..
29/03TEMPEST THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
29/03Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31..
29/03Tempest Reports Year End 2021 Financial Results and Provides Business Update
10/03Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
08/03Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AA..
09/02Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference
2021Tempest Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
2021Tempest Therapeutics, Inc. Announces Resignation of Stella Xu as a Member of Board, Eff..
2021Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
2021Tempest Therapeutics, Inc. Announces First Patient Dosed with TPST-1495 in Combination ..
2021Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach..
2021Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach..
2021Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach..
2021TEMPEST THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
2021Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
2021Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights ..
2021Tempest Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
2021Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-14..
2021Tempest to Present at Two Upcoming Investor Conferences in November
2021Tempest Therapeutics Secures Multiple Patents for Anti-Cancer Candidate TPST-1495
2021Tempest Further Bolsters Patent Portfolio with Issuance of†Multiple Patents for TPST-14..
2021Context Therapeutics Names Jennifer Minai-Azary Chief Financial Officer
2021Tempest Therapeutics : Announces Presentation at the Society for Immunotherapy of Cancer (..
2021Tempest Therapeutics : Announces Presentation at the Society for Immunotherapy of Cancer (..
2021Tempest Therapeutics : Change in Directors or Principal Officers (form 8-K/A)
2021Tempest Therapeutics : THIRD AMENDED AND RESTATED BY-LAWS OF (Form 8-K)
2021Tempest Therapeutics, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye..
2021OvaScience, Inc. has Changed its Name to Tempest Therapeutics Inc
2021Tempest Therapeutics : Doses First Patient in Phase 1b/2 Trial of T..
2021Tempest Therapeutics : Announces First Patient Dosed in Randomized Study Evaluating TPST-1..
2021Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First..
2021Tempest Therapeutics : Enters into Exclusive License Agreement with the University of Cali..
2021Tempest Therapeutics Inc. Enters into Exclusive License Agreement with the University o..
2021Tempest Therapeutics, Inc. Announces Appointment to Its Advisory Board
2021Tempest Therapeutics : to Present at Upcoming Investor Conferences
2021Tempest Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporat..
2021Tempest Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporat..
2021Tempest Therapeutics, Inc. : Results of Operations and Financial Condition, Change in Dire..
2021Tempest Therapeutics : Reports Second Quarter 2021 Financial Results and†Provides Corporat..
2021Tempest Therapeutics Inc. Reports Financial Results for the Second Quarter and Six Mont..
2021Tempest Therapeutics, Inc. Announces the Appointment of Ronit Simantov to the Company's..
2021Tempest Therapeutics : Announces Appointment of Ronit Simantov, M.D. to its Board of Direc..
2021Sector Update: Health Care Stocks Hanging Onto Slim Monday Advance
2021Sector Update: Health Care Stocks Scratching Out Narrow Rise
2021Sector Update: Health Care
2021Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
2021Tempest Therapeutics, Inc. announced that it has received $30 million in funding from a..
Volgende evenement op TEMPEST THERAPEUTICS, INC.